» Articles » PMID: 20185014

Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals with and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

Overview
Journal Am J Cardiol
Date 2010 Feb 27
PMID 20185014
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to determine cardiovascular event rates in diabetic patients and nondiabetic subjects from the REACH Registry with established coronary artery disease, cerebrovascular disease, peripheral arterial disease, or multiple risk factors for atherothrombosis. REACH is an international, prospective, and contemporaneous cohort of patients with > or = 3 atherothrombotic risk factors only or established atherothrombotic disease, of which 30,043 have diabetes. The main outcomes after 1-year follow-up were cardiovascular death, myocardial infarction, stroke, major adverse cardiovascular events (MACEs; cardiovascular death, myocardial infarction, or stroke), and MACEs/hospitalization. The MACE rate at 1 year was positively related to the number of atherothrombotic anatomic sites in diabetic patients and nondiabetic subjects, and the rate was higher in those with (3.8%) than without (3.0%, p <0.001) diabetes. Diabetic patients with risk factors only had a lower MACE rate than nondiabetic subjects or diabetic patients with established atherothrombotic disease (2.2% vs 4.0% or 6.0%, respectively, p <0.001 for the 2 comparisons). These differences persisted after adjusting for gender and age. In conclusion, diabetic patients in the REACH Registry have an increased risk of cardiovascular events compared to nondiabetic subjects related to the number of atherothrombotic sites. Although increasing risk, diabetes may not be truly equivalent to previous atherothrombotic events on new cardiovascular event rates.

Citing Articles

Mechanisms and Therapeutic Strategies for Myocardial Ischemia-Reperfusion Injury in Diabetic States.

Xue J, Zhuang J, Wang X, Meng T, Wu J, Zhang X ACS Pharmacol Transl Sci. 2024; 7(12):3691-3717.

PMID: 39698288 PMC: 11651189. DOI: 10.1021/acsptsci.4c00272.


Secondary prevention therapies following percutaneous coronary intervention or acute coronary syndrome in patients with diabetes mellitus.

Planchat A, Gencer B, Degrauwe S, Musayeb Y, Roffi M, Iglesias J Front Cardiovasc Med. 2024; 11:1436332.

PMID: 39650149 PMC: 11621092. DOI: 10.3389/fcvm.2024.1436332.


Vascular Disease and Diabetes.

Komai H Ann Vasc Dis. 2024; 17(2):109-113.

PMID: 38919320 PMC: 11196175. DOI: 10.3400/avd.ra.24-00010.


Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S J Atheroscler Thromb. 2023; 31(6):641-853.

PMID: 38123343 PMC: 11150976. DOI: 10.5551/jat.GL2022.


The impact of diabetic nephropathy and severe diabetic retinopathy on chronic limb threatening ischemia risk in individuals with type 1 diabetes: a nationwide, population study.

Harjutsalo V, Kallio M, Forsblom C, Groop P Lancet Reg Health Eur. 2023; 28:100594.

PMID: 37180744 PMC: 10173269. DOI: 10.1016/j.lanepe.2023.100594.